Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 260Carcinoma, Non-Small-Cell Lung 125Glioblastoma 105Breast Neoplasms 104Ovarian Neoplasms 96Carcinoma, Hepatocellular 88Brain Neoplasms 71Rectal Neoplasms 69Neoplasm Metastasis 69Lung Neoplasms 65Colonic Neoplasms 58Neoplasms 57Glioma 52Fallopian Tube Neoplasms 44Carcinoma, Renal Cell 36Gliosarcoma 31Pancreatic Neoplasms 30Melanoma 27Liver Neoplasms 26Stomach Neoplasms 21Astrocytoma 21Adenocarcinoma of Lung 21Recurrence 20Kidney Neoplasms 19Colorectal Cancer Metastatic 17Triple Negative Breast Neoplasms 16Esophageal Neoplasms 15Uterine Cervical Neoplasms 14Sarcoma 13Prostatic Neoplasms 13

Interventions

Imatinib Mesylate 32regorafenib 9Sunitinib 9Laparoscopy 5Dasatinib 4Blood Specimen Collection 4pazopanib 3nilotinib 3Surveys and Questionnaires 3Surgical Procedures, Operative 3Paclitaxel 3Observation 3spartalizumab 2ripretinib 2envafolimab 2binimetinib 2apatinib 2Temozolomide 2Neoadjuvant Therapy 2Ipilimumab 2Gemcitabine 2Docetaxel 2Cisplatin 2Carboplatin 2Capecitabine 2CTLA-4 Antigen 2Biopsy, Fine-Needle 2Biopsy 25-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastrointestinal Stromal Tumors × Bevacizumab × Clear all
NCT00780494 2025-01-14

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

Stanford University

Phase 2 Completed
35 enrolled 13 charts
GastrointestinalSarcoma

Stomach Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡